由麦克马斯特大学领导的全球临床试验发现，抗抑郁药氟伏沙明在减轻长新冠患者疲劳症状方面具有显著效果。1该随机对照试验共纳入399名巴西成人患者，这些患者在确诊感染SARS-CoV-2后至少持续90天的疲劳症状。1试验将参与者随机分为三组，分别接收氟伏沙明、二甲双胍或安慰剂治疗，疗程为60天。1结果表明，氟伏沙明在减轻疲劳方面优于安慰剂，统计分析显示该药物比安慰剂更有效的概率达99%。1
相比之下，二甲双胍未能产生相同的治疗效果，尽管早期研究表明在COVID感染初期服用该药可降低后来患长新冠的风险。1研究论文已发表在《内科学年鉴》上，为医疗工作者提供了首个有强有力证据支持的药物治疗选择。1该研究由加拿大、巴西和美国的研究人员联合领导，临床试点位于巴西贝洛奥里藏特市和米纳斯吉拉斯州，由拉托纳基金会资助。1长新冠目前全球估计影响约6500万人。1
A global clinical trial led by McMaster University has found that fluvoxamine, a widely used antidepressant marketed as Luvox, significantly reduces fatigue in long COVID patients and improves their quality of life.1 The randomized controlled trial involved 399 Brazilian adults who experienced fatigue for at least 90 days following confirmed SARS-CoV-2 infection, with results published in Annals of Internal Medicine.1 Statistical analysis showed a 99 percent probability that fluvoxamine was more effective than placebo at relieving fatigue, marking the first strongly evidence-supported pharmacological option for treating long COVID fatigue.1
The study divided participants into three groups receiving either fluvoxamine, metformin, or placebo over a 60-day treatment period.1 While metformin failed to replicate the same benefits despite early research suggesting it could reduce long COVID risk when taken early in COVID infection, fluvoxamine demonstrated clear superiority over placebo.1 The trial was conducted across sites in Belo Horizonte and Minas Gerais state in Brazil by researchers from Canada, Brazil, and the United States.1
Long COVID affects an estimated 65 million people globally.1 Edward Mills stated that this represents "an important step for patients who have long been seeking evidence-based treatment options," while Jamie Forrest noted that "for the first time, this trial provides healthcare workers with strong evidence that a medication can help reduce long COVID fatigue."1 The research was funded by the Latona Foundation.1
评论
还没有评论，欢迎留下第一条。